Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1

Conditions

Vomiting 6Nausea 3Neoplasms 2Uterine Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × fosaprepitant × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT01490060 2016-04-11

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

M.D. Anderson Cancer Center

Phase NA Completed
47 enrolled 6 charts
Sarcoma

Nausea, Neoplasms, Sarcoma, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡